Previous editions of BioBucks

Four responders, $550M. A killed Phase 3 that doubled the stock. FDA says yes early.

GSK's ADC makes history in China while the FDA turns the lights back on.

Roche and Ionis stumble, GSK ditches Alector, and gene editing gets a federal check.

Ipsen lands Phase III migraine data, Tarsus adds IRX-101, and FDA pauses new CRL disclosures.

Vera flips to launch mode in IgA nephropathy, Kailera's oral GLP-1 clears Phase 3, and AZ crashes Merck's COPD party.

Vertex's biggest-ever check, Genmab's bispecific clears Europe, and CMS takes an axe to 340B.

Plus AZ's fourth CSPC raid, United's $300M thymus bet, and a soft-jobs tape.

Roche posts a phase III KRAS win, Orca clears the FDA, and Novartis lands an EU SMA nod.

Ipsen buys Memo, Canada clears generic Wegovy, and Boulevard rents a $1.6B China T-cell engager.

Sanofi clears a Pompe hurdle, Roche grabs a TED PDUFA, and Nuvectis grabs $100M while the window's open.

Ipsen buys Kartos, Viridian gets its TED approval, and Tavneos faces a sharper regulatory overhang.

Biogen takes the red pen to Apellis; Ionis hands off zilganersen

Trop-2 ADC goes frontline, an antisense pancreatitis first, and a $10.6B tender clock now ticking.

Two Big Pharmas circle a gene-therapy bankruptcy, and an oral GLP-1 posts 11.5%.

AbbVie buys its way into eczema. Plus Merck's TL1A Phase 3 win and Sanofi's EU MS nod.

MoonLake tees up Investor Day, Washington probes German pricing, and biotech tape stays oddly selective.

Biogen shops immunology, Kardigan banks $400M, and biotech tapes over a weak broader close.

Moderna faces the FDA panel, Lilly grabs more pain, and Merck writes another AI check.

Intellia rewrites HAE, Spyre stokes TL1A takeout math, and Neumora cuts a third of staff.

J&J leads on Phase 3 myeloma, Sanofi expands Tzield, and Lilly adds a CLL win as biotech stays bid.

Takeda bodies Sotyktu in a head-to-head, Penumbra gets its stroke green light, and Stockholm keeps the EHA data spigot open.

Hot CPI and an oil-fueled risk-off dragged biotech down with the tape — even a record IPO and a Phase 3 win couldn't keep the screen green.

GSK reaches for the checkbook, Parabilis breaks the IPO record, and AstraZeneca gatecrashes the GLP-1 party.

Incyte spends $2B dodging its own patent cliff, J&J buys into degraders sight-unseen, AZ's diet pill stays in the race — and biotech somehow still closes red.

Roche hands Nurix $700M for a BTK degrader, ADA can't stop shipping obesity data, and a chip rout drags the tape to its worst day since October.